Meet with Odylia at JP Morgan Healthcare Conference
Representatives from Odylia Therapeutics will be at the JP Morgan Healthcare Conference in San Francisco in January. We&...
Odylia Therapeutics is a non-profit corporation working to bring treatments for rare eye disease from the lab into humans using genetic therapies. Today, there are more than 300 known genetic forms of Inherited Retinal Disease (IRD) that lead to blindness, with some of these interfering with other sensory mechanisms like hearing and balance. Most are extremely rare, impacting less than one in a million people worldwide.
Although pre-clinical proof-of-concept treatments exist for some of these diseases, because they are so rare, there is little commercial interest in them. Odylia was formed to find a way to move these potential therapies into clinical trials to protect and restore the vision of those going blind.
Although pre-clinical proof-of-concept treatments exist for some of these diseases, because they are so rare, there is little commercial interest in them. Odylia was formed to find a way to move these potential therapies into clinical trials to protect and restore the vision of those going blind.
Representatives from Odylia Therapeutics will be at the JP Morgan Healthcare Conference in San Francisco in January. We&...
Atlanta, GA November 4, 2019 – Ashley Winslow, Ph.D, joins Odylia Therapeutics as Chief Scientific Officer. ...
Atlanta, GA October 1, 2019 – Gregory Robinson, Ph.D., joins the Advisory Board of Odylia Therapeutics, a nonprofit biot...